TCL Archive Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up December 26, 2014
TCL Archive In Brief: FDA’s Burlington Moves to Wyeth-Ayerst; NAS Award to Beckman; Genetics Online February 5, 1999